NMTC — Neuroone Medical Technologies Cashflow Statement
0.000.00%
Last trade - 00:00- $29.82m
- $27.14m
- $3.45m
Annual cashflow statement for Neuroone Medical Technologies, fiscal year end - September 30th, USD millions except per share, conversion factor applied.
2019 September 30th | 2020 September 30th | 2021 September 30th | 2022 September 30th | 2023 September 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -6.78 | -13.6 | -9.95 | -10 | -11.9 |
| Depreciation | |||||
| Non-Cash Items | 1.46 | 10.6 | 1.78 | 1.15 | 1.2 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.102 | -0.43 | -0.513 | 1.21 | -2.43 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Cash from Operating Activities | -5.4 | -3.43 | -8.6 | -7.52 | -12.9 |
| Capital Expenditures | -0.123 | -0.122 | -0.067 | -0.275 | -0.384 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | — | — | — | -2.97 | 3.03 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -0.123 | -0.122 | -0.067 | -3.24 | 2.65 |
| Financing Cash Flow Items | -0.689 | -1.51 | -1.25 | -1.33 | -1.07 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 5.77 | 7.32 | 11.5 | 12 | 7.4 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 0.247 | 3.78 | 2.86 | 1.26 | -2.84 |